Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. P.G.M. (Peter) Mol

Publicaties

Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis

Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making

Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry

Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020

Preferences about Future Alzheimer’s Disease Treatments Elicited through an Online Survey Using the Threshold Technique

Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis

Lees meer

Pers/media

Towards a more efficient use of registry-based real-world data in Europe: the More-EUROPA project

Peter Mol en Patrick Vrijlandt namens Nederland in het Europese CHMP

Oratie Peter Mol over kennisuitwisseling tussen wetenschap en medicijnautoriteit